Anirban Maitra, Director of the Perlmutter Cancer Center, shared a post on LinkedIn:
“Looking forward to welcoming the Queen of RAS Inhibitors Dr. Mallika Singh to NYU Langone Health on Monday, hosted by my dear colleague Iannis Aifantis.
This class of drugs is going to transform oncologic care in some of the toughest cancers and I am looking forward to Mallika’s talk. We will also soon have some exciting news to share on how the Perlmutter Cancer Center will coalesce efforts around offering more clinical trials targeting abnormal RAS signaling in cancers (and all the science that will accompany these trials). Stay tuned!”
Other articles about RAS Inhibitor on OncoDaily.